Rights and permissions
About this article
Cite this article
Rosiglitazone: clinical, economic gains in patients with type 2 DM. Pharmacoecon. Outcomes News 429, 4 (2003). https://doi.org/10.1007/BF03276746
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03276746